On January 24, 2026, a launch event was held for the special issue on Alzheimer’s disease (AD) Aβ immunotherapy in Journal of Xi’an Jiaotong University (Medical Sciences). This special issue is the first dedicated collection in China specifically planned around AD Aβ immunotherapy. It covers all major aspects of AD Aβ immunotherap...
On January 16, 2026, Professor Han Suxia, Vice President of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), led a delegation to the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, for a special study visit, aiming to address challenges in building a cell therapy center...
On January 10, 2026, the “West China Forum on Technology-Enabled Ostomy Development and the Academic Conference of the West China Intestinal Ostomy Nursing Specialty Alliance” was successfully held at the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU). More than 100 nursing professionals from 76 member instituti...
A clinical research project entitled “Stem Cell Therapy for Pre-Liver Failure”, led by Professor He Yingli from the Department of Infectious Diseases of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), passed the final review and was registered with the National Stem Cell Committee on December 17, 2025. On Ja...
Immune checkpoint blockade (ICB) therapy has markedly improved outcomes for multiple cancers; however, its efficacy remains limited in prostate cancer and other “immune-cold” tumors, with clinical response rates of less than 5%. In theory, radiotherapy can enhance antitumor immunity by inducing DNA damage and activating the cGAS-STIN...
